当前位置 : 首页 >> 师资队伍 >> 专任教师 >> 预防医学系 >> 教授 >> 正文
教授

李得加

作者:   发布时间:2014-09-17  浏览次数:


 

姓名:李得加

职务、职称: 副系主任、教授、博士生导师、楚天学子、公共卫生与预防医学实验教学中心主任、武汉大学人口与健康研究中心人口发展与环境健康研究室主任。

系别: 预防医学学系

联系电话:18271470520

邮箱:80938299@qq.com

个人简介:

2005年博士毕业于武汉大学生命科学学院,2006年受Dongsheng Duan教授邀请赴美国从事博士后研究,在美国University of Missouri-columbia 工作期间,发表SCI论文11篇。2011年回国后,在The Journal of Biological Chemistry, Molecuar Therapy-Nucleic Acids, Molecular Therapy, Molecular Cancer, Genome Medicine等与本专业相关的专业杂志上发表通讯作者论文32篇。其中两篇影响因子10分以上,4篇论文入选2017ESI高被引论文,3篇论文入选2018ESI高被引论文,1篇论文入选2018ESI热点论文,4篇论文入选2019ESI高被引论文,3篇论文入选2020ESI高被引论文,单篇被引次数高达212次,第一作者和通讯作者论文总被引次数1800多次,篇平均被引次数33.82H-index=25。另外合作出版中、英文专著两部。现为农工党武大医学部支部主委,湖北省预防医学会理事,武汉市预防医学会环境卫生学委员会常务副主任委员,美国基因与细胞治疗协会会员。SCI期刊Current Pharmaceutical Design特刊客座编辑,中科院二区SCI期刊journal of translational medicine副主编。国际期刊Oncogene, American Journal of Pathology, Cancer Letters, Molecular Cancer, International Journal of Cancer, Scientific Report, Oncotarget, Molecular Therapy-Nucleus Acids, CarcinogenesisAging-USSCI期刊审稿人。


主要研究领域:肿瘤免疫学、非编码RNA的生物学功能、骨质疏松与肌萎缩

主持或参与科研项目情况:

新肺癌分子标记物 miRNA 在肺癌发生、诊断和治疗中的作用(武汉市高新技术产业科技创新团队培养计划) 项目负责人

Sirt1对萎缩肌肉再生能力影响机制的研究(湖北省自然科学基金) 项目负责人

Sirt1在杜氏肌营养不良症中作用机制的研究 (国家自然科学基金面上项目) 项目负责人

综合干预对Klotho基因表观遗传影响及其与心血管危险因素关联性研究(国家自然科学基金面上项目) 第一参与人

长链非编码RNA LINC00301在非小细胞肺癌中的作用及其分子机制(江西省科技计划重点项目) 项目负责人

近三年代表性通讯作者论文:

1. Hu, Wei; Liu, Cong; Bi, Zhuo-Yue; Zhou, Qun; Zhang, Han; Li, Lin-Lin; Zhang, Jian; Zhu, Wei; Song, Yang-Yi-Yan; Zhang, Feng; Yang, Hui-Min; Bi, Yong-Yi; He, Qi-Qiang; Tan, Gong-Jun; Sun, Cheng-Cao; Li, De-Jia, Comprehensive landscape of extracellular vesicle-derived RNAs in cancer initiation, progression, metastasis and cancer immunology, Molecular Cancer, 2020, 19(1), DOI: 10.1186/s12943-020-01199-1IF 15.302

2. Chengcao SunWei ZhuShujun LiWei HuDe-Jia Li. FOXC1-mediated LINC00301 facilitates tumor progression and triggers an immune-suppressing microenvironment in non-small cell lung cancer by regulating the HIF1α pathway. Genome Med. 2020 Sep 2;12(1):77. doi: 10.1186/s13073-020-00773-y (IF 10.675)

3. Zhu, Wei; Li, Linlin; Li, Dejia. Rs11655237 polymorphism of LINC00673 affects the prognosis of cervical cancer by interfering with the interaction between LINC00673 and microRNA-1231, J Cell Physiol, 2020, 235(11): 8155-8166. (IF 5.546)

4. Sun CC, Li SJ, Hu W, Zhang J, Zhou Q, Liu C, Li LL, Songyang YY, Zhang F, Chen ZL, Li G, Bi ZY, Bi YY, Gong FY, Bo T, Yuan ZP, Hu WD, Zhan BT, Zhang Q, He QQ, Li DJ: Comprehensive analysis of the expression and prognosis for e2fs in human breast cancer. Molecular Therapy. 2019.27(6):1153-1165.(IF 8.402)

5. Sun, CC; Li, SJ; Chen, ZL; Li, G; Zhang, Q ; Li, DJ, Expression and Prognosis Analyses of Runt-Related Transcription Factor Family in Human Leukemia, Molecular Therapy-Oncolytics, 2019, 12:: 103-111. (IF 4.115)

6. Sun CC, Zhou Q, Hu W, Li SJ, Zhang F, Chen ZL, Li G, Bi ZY, Bi YY, Gong FY, Bo T, Yuan ZP, Hu WD, Zhan BT, Zhang Q, Tang QZ, Li DJ. Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma. Aging (Albany NY). 2018. 10(5):973-987. (IF 4.831)

7. Cheng-Cao Sun ; Ling Zhang; Guang Li; Shu-Jun Li; Zhen-Long Chen; Yun-Feng Fu; Feng-Yun Gong; Tao Bai; Ding-Yu Zhang; Qing-Ming Wu ; De-Jia Li, The lncRNA PDIA3P Interacts with miR-185-5p to Modulate Oral Squamous CellCarcinoma Progression by Targeting Cyclin D2 , Molecular Therapy - NucleicAcids, 2017.12.15, 9: 100~110. (IF 7.032)

8. Jing-Yu Pan; Cheng-Cao Sun; Zhuo-Yue Bi; Zhen-Long Chen; Shu-Jun Li; Qing-Qun Li; Yu-Xuan Wang; Yong-Yi Bi; De-Jia Li , miR-206/133b Cluster: A Weapon against Lung Cancer? Molecular Therapy - Nucleic Acids, 2017.9.15, 8: 442~449 ; (IF 7.032)

9. Zhou, Qun; Huang, Shao-Xin; Zhang, Feng; Li, Shu-Jun; Liu, Cong; Xi, Yong-Yong; Wang, Liang; Wang, Xin; He, Qi-Qiang; Sun, Cheng-Cao; Li, De-Jia , MicroRNAs: A novel potential biomarker for diagnosis and therapy in patients with non-small cell lung cancer, Cell Proliferation, 2017.10.8, 50(56). (IF 5.753)

10. Pan, JY, Zhang, F, Sun, CC, Li, SJ, Li, G, Gong, FY, He, J, Hua, RX, Hu, WD, Yuan, ZP, Wang, X, He, QQ and Li, DJ. MiR-134: a human cancer suppressor? Mol Ther Nucleic Acids, 2017. 6(1): doi: 10.1016/j.omtn.2016.11.003. (IF 7.032)

11. Sun, CC, Li, SJ, Zhang, F, Zhang, Y, Zuo, Z, Xi, YY, Wang, L, and Li, DJ. The novel miR-9600 suppresses tumor progression and promotes paclitaxel sensitivity in non-small cell lung cancer (NSCLC) through altering STAT3 expression. Mol Ther Nucleic Acids, 2016. 5(11): e387. (IF 7.032)

12. Sun, CC, Li, SJ, Li G, Hua, R, Zhou, XH, Li, DJ. Long intergenic non-coding RNA 00511 acts as an oncogene in non-small cell lung cancer by binding to EZH2 and suppressing p57. Mol Ther Nucleic Acids, 2016. 5(11): e385. (IF 7.032)